Globally, malignancies cause one out of six mortalities, which is a serious health problem. Cancer therapy has always been challenging, apart from major advances in immunotherapies, stem cell transplantation, targeted therapies, hormonal therapies, precision medicine, and palliative care, and traditional therapies such as surgery, radiation therapy, and chemotherapy. Natural products are integral to the development of innovative anticancer drugs in cancer research, offering the scientific community the possibility of exploring novel natural compounds against cancers. The role of natural products like Vincristine and Vinblastine has been thoroughly implicated in the management of leukemia and Hodgkin’s disease. The computational method is the initial key approach in drug discovery, among various approaches. This review investigates the synergy between natural products and computational techniques, and highlights their significance in the drug discovery process. The transition from computational to experimental validation has been highlighted through in vitro and in vivo studies, with examples such as betulinic acid and withaferin A. The path toward therapeutic applications have been demonstrated through clinical studies of compounds such as silvestrol and artemisinin, from preclinical investigations to clinical trials. This article also addresses the challenges and limitations in the development of natural products as potential anti-cancer drugs. Moreover, the integration of deep learning and artificial intelligence with traditional computational drug discovery methods may be useful for enhancing the anticancer potential of natural products.

Carbon constraints, as well as the growing hazard of greenhouse gas emissions, have accelerated research into all possible renewable energy and fuel sources. Microbial electrolysis cells (MECs), a novel technology able to convert soluble organic matter into energy such as hydrogen gas, represent the most recent breakthrough. While research into energy recovery from wastewater using microbial electrolysis cells is fascinating and a carbon-neutral technology that is still mostly limited to lab-scale applications, much more work on improving the function of microbial electrolysis cells would be required to expand their use in many of these applications. The present limiting issues for effective scaling up of the manufacturing process include the high manufacturing costs of microbial electrolysis cells, their high internal resistance and methanogenesis, and membrane/cathode biofouling. This paper examines the evolution of microbial electrolysis cell technology in terms of hydrogen yield, operational aspects that impact total hydrogen output in optimization studies, and important information on the efficiency of the processes. Moreover, life-cycle assessment of MEC technology in comparison to other technologies has been discussed. According to the results, MEC is at technology readiness level (TRL) 5, which means that it is ready for industrial development, and, according to the techno-economics, it may be commercialized soon due to its carbon-neutral qualities.

Biofuel is one of the best alternatives to petroleum-derived fuels globally especially in the current scenario, where fossil fuels are continuously depleting. Fossil-based fuels cause severe threats to the environment and human health by releasing greenhouse gases on their burning. With the several limitations in currently available technologies and associated higher expenses, producing biofuels on an industrial scale is a time-consuming operation. Moreover, processes adopted for the conversion of various feedstock to the desired product are different depending upon the various techniques and materials utilized. Nanoparticles (NPs) are one of the best solutions to the current challenges on utilization of biomass in terms of their selectivity, energy efficiency, and time management, with reduced cost involvement. Many of these methods have recently been adopted, and several NPs such as metal, magnetic, and metal oxide are now being used in enhancement of biofuel production. The unique properties of NPs, such as their design, stability, greater surface area to volume ratio, catalytic activity, and reusability, make them effective biofuel additives. In addition, nanomaterials such as carbon nanotubes, carbon nanofibers, and nanosheets have been found to be cost effective as well as stable catalysts for enzyme immobilization, thus improving biofuel synthesis. The current study gives a comprehensive overview of the use of various nanomaterials in biofuel production, as well as the major challenges and future opportunities.

Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.

Combustion is an essential process for humanity, but it has created turbulence in society due to the pollutant emissions from the partial completion of its process and its byproducts. The regular population is unaware of the repercussions being faced in terms of health deterioration, product quality degradation, biodiversity loss, and environmental harm. Although strategic planning against the effects is being applied sideways by the authorities to the local population and industrial facilities, the awareness in the local population is still minimal. The indicators for bioremediation being required, observed through increased sales of pharmaceutical medicines and supplements, air filters, and new techniques, include smog, elevation in respiratory disease, health immune system deterioration, decreasing life span, increasing mortality rate, and degradation in the food and water quality. This article gives a brief overview of the problems being faced due to uncontrolled combustion activities, the sources of pollutants, their creation, emission, and dispersal process, along with the mitigation techniques developed to overcome the after-effects on human health and environment.

Monkeypox virus (Mpox virus) is a zoonotic orthopoxvirus that has gained increased global attention due to recent outbreaks. The current review reports the latest update of Mpox cases from 25 February 2022 to 29 April 2025. It also evaluates the possible major complications in human life caused by Mpox. In early 2022, more than 40 countries reported Mpox outbreaks. As of 12 June 2024, the global case count for the 2022–2023 Mpox outbreak was 97,281 confirmed cases, in 118 countries. The World Health Organization (WHO) declared the Mpox virus, a zoonotic disease, a public health emergency of international concern (PHEIC) on 14 August 2024. Mpox symptoms include fever, headache, muscle pain, and face-to-body rashes. The review also highlights Mpox virus replication, genomics, pathology, transmission, diagnosis, and antiviral therapies. The 2022 outbreak is also discussed in detail. The coinfection of HIV in patients infected with Mpox is also discussed. The evolving Mpox epidemiology has raised concerns about the disease’s increasing spread in non-endemic countries, emphasizing the urgent need for control and prevention. The discussion on preventive measures, including vaccination, suggests that cross-protection against Mpox may be possible using orthopoxvirus-specific antibodies. Although there are no specific antiviral drugs available, certain drugs, such as tecovirimat, cidofovir, and ribavirin, are worth considering.